KRAS is mutated in 25–30% of nonsmall cell lung cancer, of which c.35G>A (G12D) and codon 12 mutations are common in lung carcinoma (~ 18%)8 and ovarian cancer (~ 5.8%)9, respectively. Here, KRAS is linked to lung carcinoma.